Synflorix™ (10-valent pneumococcal conjugate vaccine; GlaxoSmithKline Biologicals ... following priming was observed between continents. 2,3 In European studies, Synflorix™ was proven to ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in this ...

In the past year, shares of Merck have plunged 21.7% compared with the industry’s decrease of 2.6%. Image Source ... to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 ...

2 controlled studies in South Africa evaluated ... meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein ... After shipping, Prevnar 20 may arrive at temperatures between 2 ºC to 25 ºC (36 ºF to 77 ºF). Upon receipt, store ...

Advancement to Stage 2 follows a blinded assessment of ... tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal ...